biostudies-literatureUnknown20(1)Droitcourt CFrench Ministry of Social Affairs and Health, France<h4>Background</h4>Atopic dermatitis is a highly prevalent, chronic, relapsing disease in both adults and children. On the severity spectrum, lower-end patients benefit from small amounts of topical anti-inflammatory treatments (TAT), whereas higher-end patients need systemic immunosuppressants; in-between patients are treated with TAT and phototherapy. The major therapeutic challenge in this population is the long-term control of disease activity, and the current TAT-based pro-active strategy does not meet all their needs. Immunosuppressants are used as long-term control add-on treatments, but they are restricted to the most severely affected patients because of safety concerns. In addition, neither immunosuppressants nor other strategies have been properly evaluated in the long term despTrials184https://www.ebi.ac.uk/biostudies/studies/S-EPMC6434814biostudies-literatureA new phototherapy regimen during winter as an add-on therapy, coupled with oral vitamin D supplementation, for the long-term control of atopic dermatitis: study protocol for a multicentre, randomized, crossover, pragmatic trial - the PRADA trial.PMC6434814Weiborn MOger ESeneschal JDarrieux LPlantin PBarbaud ASoria AVermersch AGroupe de Recherche sur l’Eczéma Atopique de la Société Française de Dermatologie (GREAT)Misery LPhan ABrenaut EStaumont-Salle DDroitcourt CTaieb AAdamski HChabbert CDupuy AMaruani AViguier MSkowron FNosbaum ABarbarot SMaillard HfalseA new phototherapy regimen during winter as an add-on therapy, coupled with oral vitamin D supplementation, for the long-term control of atopic dermatitis: study protocol for a multicentre, randomized, crossover, pragmatic trial - the PRADA trial.<h4>Background</h4>Atopic dermatitis is a highly prevalent, chronic, relapsing disease in both adults and children. On the severity spectrum, lower-end patients benefit from small amounts of topical anti-inflammatory treatments (TAT), whereas higher-end patients need systemic immunosuppressants; in-between patients are treated with TAT and phototherapy. The major therapeutic challenge in this population is the long-term control of disease activity, and the current TAT-based pro-active strategy does not meet all their needs. Immunosuppressants are used as long-term control add-on treatments, but they are restricted to the most severely affected patients because of safety concerns. In addition, neither immunosuppressants nor other strategies have been properly evaluated in the long term desp2019-01-01T00:00:00Z2019 Mar2026-05-03T12:14:50.354Z2019-06-05T15:44:38ZS-EPMC64348143090992310.1186/s13063-019-3276-9